Holman Division of Endocrinology, Diabetes & Metabolism Publications
Research conducted by NYU Langone’s Holman Division of Endocrinology, Diabetes, and Metabolism appears in leading academic and medical publications.
Zodasiran, an RNAi therapeutic targeting ANGPTL3, for treating patients with homozygous familial hypercholesterolaemia (GATEWAY): an open-label, randomised, phase 2 trial
Lancet. Diabetes & endocrinology. 2026 Feb ; 14:123-136
Defining prediabetes remission as a distinct prevention endpoint
Lancet. Diabetes & endocrinology. 2026 Feb ; 14:100-102
Endothelial Cell Regulation of Lipid Uptake During Feeding and Fasting
Arteriosclerosis, thrombosis, & vascular biology. 2026 Feb ; 46:e323501
Joint Modeling of Longitudinal Biomarker and Survival Outcomes with the Presence of Competing Risk in the Nested Case-Control Studies with Application to the TEDDY Microbiome Dataset
Bioinformatics. 2026 Jan 22;
A Road Map to Understanding Cardiovascular Disease in Diabetes: From the AHA Strategically Focused Research Network in Cardiometabolic Health and Type 2 Diabetes
Circulation research. 2026 Jan 16; 138:e325798
Noc1 downregulation induces nucleolar stress and upregulates p53 isoforms, with a robust increase of the truncated p53E isoform in Drosophila wing discs
G3 : genes - genomes - genetics. 2026 Jan 14;
Personalized dietary feedback mediates the association of dietary self-monitoring adherence and weight loss: a post-hoc analysis of the Personal Diet Study
Journal of nutrition. 2026 Jan 13; 101364
Non-remnant triglyceride-rich lipoproteins due to lipoprotein lipase deficiency increase atherosclerosis in mice
Nature communications. 2026 Jan 03; 17:1458